| |
Naïve patients
(N=407) |
Switch
(N=696) |
Failure
(N=601) |
Total
(N=1704) |
| Sex, N (%) men |
295 (72.5) |
483 (69.4) |
398 (66.2) |
1176 (69) |
| Age, median [Q1-Q3] years |
41 [23.5-48] |
44 [38-50] |
42 [36-48] |
43 [36-49] |
| Lenght of known infection, median [Q1-Q3] years |
2 [0.3-7.8] |
9.2 [4-14.6] |
11.5 [6.6-16] |
8.7 [2.9-14.5] |
| Hepatitis co-infection, N (%) |
83 (20.4) |
161 (23.1) |
167 (27.8) |
411 (24.1) |
| Previous CDC class C event, N (%) |
85 (20.9) |
209 (30) |
179 (29.8) |
473 (27.8) |
| Baseline VL, median [Q1-Q3] log10 copies/mL |
4.8 [4.1 – 5.3] |
1.6 [1.6 – 1.6] |
3.9 [2.6 – 4.8] |
2.5 [1.7 – 4.5] |
| Patients with baseline VL ≥ 5 log10 copies/mL (%) |
41.2 |
- |
18.5 |
15.1 |
| Baseline CD4 cells/mm3, median [Q1-Q3] |
239,2 [111-319] |
512,4 [345-670] |
286 [167-456] |
354,7 [211-558] |
| Baseline CD4 cells <200/mm3 (%) |
40.4 |
8.1 |
30.8 |
23 |
| Nadir CD4 cells/mm3, median [Q1-Q3] |
222 [104-289] |
177 [71-264] |
174 [64-261] |
184 [74-272] |
| Number of previous regimens, median [Q1-Q3] |
- |
3 [1-5] |
3 [2-5] |
3 [3-5] |
| Treatment strategies |
| 3 drugs in the regimen, N (%) |
373 (92) |
664 (95) |
485 (81) |
1522 (89) |
| ABC/3TC + 1 NNRTI, N (%) |
36 (9) |
241 (35) |
49 (8) |
326 (19) |
| ABC/3TC + 1 bPI, N (%) |
211 (52) |
279 (40) |
301 (50) |
791 (46) |
| ABC/3TC + AZT, N (%) |
119 (29) |
115 (16) |
117 (19.5) |
351 (21) |
| Other, N (%) |
7 (2) |
29 (4) |
18 (3.5) |
54 (3) |
| 4 drugs or more in the regimen, N (%) |
32 (8) |
26 (4) |
113 (19) |
171 (10) |
“Naïve patients”: ABC/3TC used as part of the first regimen, “switch”: as part of a switch strategy in patients with VL below detection, “failure” as part of a rescue regimen
in patients with a previous failing regimen; VL=viral load
|
